Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

143 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Protocol compliance in a multicentric phase III trial investigating scheduled adaptive radiotherapy and dose painting in head and neck cancer.
de Leeuw ALMP, Giralt J, Tao Y, Benavente S, Nguyen TF, Hoebers FJP, Hoeben A, Terhaard CHJ, Lee LW, Friesland S, Steenbakkers RJHM, Tans L, van Kranen SR, van de Kamer JB, Bartelink H, Rasch CRN, Sonke JJ, Hamming-Vrieze O. de Leeuw ALMP, et al. Among authors: hoebers fjp. Radiother Oncol. 2024 Nov 9;202:110612. doi: 10.1016/j.radonc.2024.110612. Online ahead of print. Radiother Oncol. 2024. PMID: 39522824
Randomized controlled trial to identify the optimal radiotherapy scheme for palliative treatment of incurable head and neck squamous cell carcinoma.
Al-Mamgani A, Kessels R, Verhoef CG, Navran A, Hamming-Vrieze O, Kaanders JHAM, Steenbakkers RJHM, Tans L, Hoebers F, Ong F, van Werkhoven E, Langendijk JA. Al-Mamgani A, et al. Radiother Oncol. 2020 Aug;149:181-188. doi: 10.1016/j.radonc.2020.05.020. Epub 2020 May 14. Radiother Oncol. 2020. PMID: 32417345 Clinical Trial.
A multicentric randomized controlled phase III trial of adaptive and 18F-FDG-PET-guided dose-redistribution in locally advanced head and neck squamous cell carcinoma (ARTFORCE).
de Leeuw ALMP, Giralt J, Tao Y, Benavente S, France Nguyen TV, Hoebers FJP, Hoeben A, Terhaard CHJ, Wai Lee L, Friesland S, Steenbakkers RJHM, Tans L, Heukelom J, Kayembe MT, van Kranen SR, Bartelink H, Rasch CRN, Sonke JJ, Hamming-Vrieze O. de Leeuw ALMP, et al. Among authors: hoebers fjp. Radiother Oncol. 2024 Jul;196:110281. doi: 10.1016/j.radonc.2024.110281. Epub 2024 Apr 16. Radiother Oncol. 2024. PMID: 38636708 Clinical Trial.
Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer.
Heukelom J, Hamming O, Bartelink H, Hoebers F, Giralt J, Herlestam T, Verheij M, van den Brekel M, Vogel W, Slevin N, Deutsch E, Sonke JJ, Lambin P, Rasch C. Heukelom J, et al. BMC Cancer. 2013 Feb 22;13:84. doi: 10.1186/1471-2407-13-84. BMC Cancer. 2013. PMID: 23433435 Free PMC article. Clinical Trial.
Tumor to cervical spinal cord standardized uptake ratio (SUR) improves the reproducibility of 18F-FDG-PET based tumor segmentation in head and neck squamous cell carcinoma in a multicenter setting.
van den Bosch S, Dijkema T, Philippens MEP, Terhaard CHJ, Hoebers FJP, Kaanders JHAM, Oyen WJG. van den Bosch S, et al. Among authors: hoebers fjp. Radiother Oncol. 2019 Jan;130:39-45. doi: 10.1016/j.radonc.2018.06.037. Epub 2018 Jul 10. Radiother Oncol. 2019. PMID: 30005954 Free article.
Biological Determinants of Chemo-Radiotherapy Response in HPV-Negative Head and Neck Cancer: A Multicentric External Validation.
van der Heijden M, Essers PBM, de Jong MC, de Roest RH, Sanduleanu S, Verhagen CVM, Hamming-Vrieze O, Hoebers F, Lambin P, Bartelink H, Leemans CR, Verheij M, Brakenhoff RH, van den Brekel MWM, Vens C. van der Heijden M, et al. Front Oncol. 2020 Jan 10;9:1470. doi: 10.3389/fonc.2019.01470. eCollection 2019. Front Oncol. 2020. PMID: 31998639 Free PMC article.
Comprehensive toxicity risk profiling in radiation therapy for head and neck cancer: A new concept for individually optimised treatment.
Van den Bosch L, van der Schaaf A, van der Laan HP, Hoebers FJP, Wijers OB, van den Hoek JGM, Moons KGM, Reitsma JB, Steenbakkers RJHM, Schuit E, Langendijk JA. Van den Bosch L, et al. Among authors: hoebers fjp. Radiother Oncol. 2021 Apr;157:147-154. doi: 10.1016/j.radonc.2021.01.024. Epub 2021 Feb 3. Radiother Oncol. 2021. PMID: 33545258 Free article.
National Protocol for Model-Based Selection for Proton Therapy in Head and Neck Cancer.
Langendijk JA, Hoebers FJP, de Jong MA, Doornaert P, Terhaard CHJ, Steenbakkers RJHM, Hamming-Vrieze O, van de Kamer JB, Verbakel WFAR, Keskin-Cambay F, Reitsma JB, van der Schaaf A, Boersma LJ, Schuit E. Langendijk JA, et al. Among authors: hoebers fjp. Int J Part Ther. 2021 Jun 25;8(1):354-365. doi: 10.14338/IJPT-20-00089.1. eCollection 2021 Summer. Int J Part Ther. 2021. PMID: 34285961 Free PMC article.
Disease outcome and associated factors after definitive platinum based chemoradiotherapy for advanced stage HPV-negative head and neck cancer.
de Roest RH, van der Heijden M, Wesseling FWR, de Ruiter EJ, Heymans MW, Terhaard C, Vergeer MR, Buter J, Devriese LA, de Boer JP, Navran A, Hoeben A, Vens C, van den Brekel M, Brakenhoff RH, Leemans CR, Hoebers F. de Roest RH, et al. Radiother Oncol. 2022 Oct;175:112-121. doi: 10.1016/j.radonc.2022.08.013. Epub 2022 Aug 13. Radiother Oncol. 2022. PMID: 35973619 Free article.
143 results